---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-429647"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2026-10-23T14:31:29+00:00"
generated_at: "2026-10-23T14:33:15.696493+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics acquires Prana in reverse merger; raises $120M PIPE, Prana holders to own 51.7% post-financing

## Summary
- Bolt acquired Prana on Oct. 23, 2026; Prana holders received 430,746 BOLT shares plus 16,360.929 Series D preferred shares convertible into 1,000 common each.
- Pre-transaction Bolt holders fall to ~11.8% pre-financing and ~6.9% post-financing; Prana holders ~88.2% then ~51.7%; PIPE investors ~41.4%.
- $120M PIPE sale of 13,995.311 Series D preferred shares plus warrants for 50% more, expected to close Oct. 26, 2026; full warrant exercise would add ~$60M gross.
- Series D pays as-if-converted dividends, has no general voting rights but must approve specified actions; votes cover conversion, Nasdaq proposals, charter amendment, 1:2-1:12 reverse split.
- Lease termination triggers $4.5M payment to HCP LS Redwood City; Dr. Sheila Gujrathi joins board and becomes Chief Strategy Officer.

## SEC filing metadata
- accession: 0001193125-26-429647
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2026-10-23T14:31:29+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 1.02, 2.01, 3.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/0001193125-26-429647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/bolt-20261023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-429647
- JSON: https://secwatch.observer/filing/0001193125-26-429647.json
- Plain text: https://secwatch.observer/filing/0001193125-26-429647.txt

## Key facts
- Executive change
  Sheila Gujrathi was appointed as Class II director at Bolt Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed to the Board as a Class II director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/0001193125-26-429647-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.